tbuckley/cabot-search huggingface dataset:
S60 Aspergillus Polymerase Chain Reaction Testing in the Severe Asthma Population: Abstract S60 Table 1
Authors: JP Farrant, H Wardman, L Holmes, L Chishimba, R Niven
Journal: Thorax (2012)

<h3>Background</h3> Allergic Broncho-Pulmonary Aspergillosis (ABPA) is associated with known pulmonary fungal colonisation and proven response to long term anti-fungal therapy. A recent trial at our site, confirmed that anti fungal therapy was effective in a group of patients with Severe Asthma with Fungal Sensitisation (SAFS). Whether these patients have pulmonary fungal colonisation remains unknown. Previous hypotheses have indicated that bowel colonisation causes an allergic reaction leading to broncho-constriction. Our hypothesis is that patients with SAFS, who respond to anti-fungal therapy, do have airway colonisation. Aspergillus polymerase chain reaction (APCR), represent a novel and more sensitive way to detect the presence of Aspergillus. <h3>Methods</h3> We have performed sputum APCR tests in clinical practise over the last 2–3 years. We reviewed a retrospective cohort of patients attending a Severe Asthma Service, whose results were stored on the Mycology results system. Patient notes were reviewed to determine patient’s total serum IgE’s, IgE’s specific to Aspergillus and anti fungal therapy status. <h3>Results</h3> 77 results were logged on the microbiology of which 70 cases were available for notes review. Of these 44 (63%) were female with an average age of 57.5 years. 26 had ABPA, 42 SAFS and 2 had neither ABPA nor SAFS, but had severe asthma. Overall 57% of ABPA or SAFS patients were APCR positive. 55% of SAFS patients were APCR positive, this number increased to 68% for those who were not taking anti-fungal therapy at the time of the test. The equivalent numbers for ABPA were 65% and 70% respectively. Neither of the 2 control severe patients had positive APCR. The full data is presented in table 1. <h3>Conclusion</h3> This data supports the concept that patients with Severe Asthma with Fungal Sensitisation (SAFS) have pulmonary colonisation with Aspergillus. Suppression of such colonisation and reduced allergic response may then be the mechanism of action for anti-fungal therapy.
Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy
Authors: Roy M. Gulick, John W. Mellors, Diane Havlir, Joseph J. Eron, Charles Gonzalez, Deborah McMahon, Douglas D. Richman, Fred T. Valentine, Leslie Jonas, Anne Meibohm, Emilio A. Emini, Jeffrey A. Chodakewitz, Paul Deutsch, Daniel Holder, William A. Schleif, Jon H. Condra
Journal: New England Journal of Medicine (1997)

The new protease inhibitors are potent inhibitors of the human immunodeficiency virus (HIV), and in combination with other antiretroviral drugs they may be able to cause profound and sustained suppression of HIV replication.In this double-blind study, 97 HIV-infected patients who had received zidovudine treatment for at least 6 months and had 50 to 400 CD4 cells per cubic millimeter and at least 20,000 copies of HIV RNA per milliliter were randomly assigned to one of three treatments for up to 52 weeks: 800 mg of indinavir every eight hours; 200 mg of zidovudine every eight hours combined with 150 mg of lamivudine twice daily; or all three drugs. The patients were followed to monitor the occurrence of adverse events and changes in viral load and CD4 cell counts.The decrease in HIV RNA over the first 24 weeks was greater in the three-drug group than in the other groups (P<0.001 for each comparison). RNA levels decreased to less than 500 copies per milliliter at week 24 in 28 of 31 patients in the three-drug group (90 percent), 12 of 28 patients in the indinavir group (43 percent), and none of 30 patients in the zidovudine-lamivudine group. The increase in CD4 cell counts over the first 24 weeks was greater in the two groups receiving indinavir than in the zidovudine-lamivudine group (P< or =0.01 for each comparison). The changes in the viral load and the CD4 cell count persisted for up to 52 weeks. All the regimens were generally well tolerated.In most HIV-infected patients with prior antiretroviral therapy, the combination of indinavir, zidovudine, and lamivudine reduces levels of HIV RNA to less than 500 copies per milliliter for as long as one year.
Abstract 2004: Effect of epigenetic drugs on melanocytes and melanoma cell lines phenotype and aggressiveness
Authors: Fernanda Molognoni, Ana Carolina Monteiro, Alice Santana Morais, Camila Ferreira Souza, Adriana Taveira Cruz, Fabiana Marcelino Melisso, Gangning Liang, Peter Anthony Jones, Miriam Galvonas Jasiulionis
Journal: Cancer Research (2011)

Abstract Melanoma is the most aggressive skin cancer because of its high resistance to currently available therapy. Like other types of cancer, melanoma is influenced by many factors, including genetic and epigenetic alterations. There are few available models that mimic different steps of melanoma progression. In this way, our laboratory developed a mouse model to study melanoma genesis. Different melanoma cell lines (i.e. 4C11- and 4C11+) were obtained as result of sequential anchorage blockade cycles of a non-tumorigenic melanocyte lineage, melan-a. Melan-a submitted to 2, 3 and 4 deadhesion cycles were also established (2C, 3C and 4C), are not tumorigenic and represent distinct phases of tumor progression. Melan-a, 4C, 4C11- and 4C11+ cells present differences in epigenetic profile, including global and gene specifc DNA methylation, posttranslational histone modifications as well DNA methyltransferases expression. Therefore, we have been interested in determining the separate and combined effects of 5-Aza-2’-deoxycytidine (5-Aza-CdR, inhibitor of DNA methylation) and Trichostatin A (TSA, inhibitor of histone deacetylases) treatment on cell phenotype and tumor characteristics. Our group already showed that TSA or 5-Aza-2’-deoxycytidine treatment causes changes in melanoma cells (4C11- and 4C11+) morphology and in in vivo tumor growth. Interestingly, TSA treatment was more efficient in diminishing 4C11- (non-metastatic melanoma) tumor growth in vivo than 5-Aza-CdR. On the other hand, 5-Aza-CdR treatment was more efficient to decrease 4C11+ (metastatic melanoma) tumor growth in vivo. Moreover, when treated with 5-Aza-CdR and TSA, 4C11- cells (a non-metastatic melanoma) give rise to hemorrhagic invasive tumors in vivo. This kind of treatment might lead to over expression of genes related to invasiveness and metastasis. We already have some candidate genes to investigate as γ-synuclein. Taken together these findings could contribute to a better understanding of epigenetic drugs treatment on melanoma and may have important clinical applications. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2004. doi:10.1158/1538-7445.AM2011-2004
DRENAJE TRANSMURAL GUIADO POR ULTRASONOGRAFÍA ENDOSCÓPICA DE ABSCESOS PANCREÁTICOS EN PACIENTES CON PANCREATITIS AGUDA GRAVE
Authors: A Velasco Guardado, A Repiso Ortega, A Álvarez Delgado, R Gómez Rodríguez, JM Carrobles, A Rodríguez Pérez
Journal: Endoscopy (2010)

Introducción: En los últimos años, el drenaje guiado por ultrasonografía endoscópica (USE) se ha constituido como una opción terapéutica eficaz para el tratamiento de colecciones pancreáticas o peripancreáticas infectadas. Evaluamos retrospectivamente la eficacia y seguridad de esta técnica.
AB0796 Clinical picture of anti-jo-1 positive anti-synthetase syndrome at presentation and during follow-up
Authors: E. Scorletti, L. Cavagna, R. Caporali, C. Fusetti, N. Boffini, C. Montecucco
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Anti-synthetase syndrome (AS) is a connective tissue disease characterized by myositis, arthritis, interstitial lung disease (ILD) and the presence of anti-synthetase antibodies, mostly anti-Jo-1. Patients with an incomplete form of AS have been described; however it is not known whether and when these patients will develop a full-blown clinical picture during the course of the disease <h3>Objectives</h3> To evaluate whether and how the clinical spectrum of patients with a diagnosis of incomplete AS changes during follow-up <h3>Methods</h3> All patients with anti-Jo-1 positive AS followed at our Department from 1991 were retrospectively evaluated for clinical features at the time of diagnosis and during follow-up. All patients had been regularly followed at our department. Two patients died during follow-up (after 57 and 106 months), whereas two patients were lost to follow-up after 92 and 118 months. All the remaining patients had their last visit after August 2011. Anti-Jo-1 positivity was confirmed in stored frozen sera from all patients using EliA Jo-1 fluoroenzyme-immunoassay (Phadia 250 automatic instrumentation, Phadia GmbH, Freiburg, Germany) <h3>Results</h3> For the purpose of this study, 18 patients (5 males/13 females) were analyzed. Median age at onset was 52.5 years (IQR 45-69) and median follow-up was 75 months (IQR 38-95). At the time of diagnosis, 8 patients (44%) had a complete form. The remaining 10 patients had an incomplete form; 5 had isolated arthritis, 3 arthritis and ILD, 1 arthritis and myositis and 1 had isolated ILD. At the last follow-up visit, a complete form of the disease was present in 14 patients (78%). Five patients with isolated arthritis developed both myositis and ILD within 3 months to 13 years, and 1 out of 3 patients with arthritis and ILD developed myositis after 2 years. Finally, the patient with isolated ILD developed arthritis after 21 months <h3>Conclusions</h3> Clinical presentation of anti-Jo-1 AS is quite variable as only 44% of patients had a complete form at onset. In particular, myositis was present in 50% of the patients diagnosed at our department and ILD in 67%. A long and careful follow-up is mandatory in patients with incomplete syndrome as myositis and ILD may occur even very late during the course of the disease <h3>Disclosure of Interest</h3> None Declared
A 3-Year M.D. — Accelerating Careers, Diminishing Debt
Authors: Steven B. Abramson, Dianna Jacob, Melvin Rosenfeld, Lynn Buckvar-Keltz, Victoria Harnik, Fritz Francois, Rafael Rivera, Mary Ann Hopkins, Marc Triola, Robert I. Grossman
Journal: New England Journal of Medicine (2013)

Interview with Dr. Richard Schwartzstein on the pros and cons of three-year medical school programs. (00:00)Download In recent decades, the length of medical training has increased, slowing the entry of new physicians into practice. Experiments with 3-year medical schools, like the one at New York University, attempt to address this delay.
IMPACT OF MYOCARDIAL BRIDGING ON CORONARY ARTERY PLAQUE FORMATION AND LONG-TERM MORTALITY AFTER HEART TRANSPLANTATION
Authors: Shigemitsu Tanaka, Kozo Okada, Hideki Kitahara, Yuhei Kobayashi, Helen Luikart, Paul Yock, Alan Yeung, Ingela Schnittger, Peter Fitzgerald, Kiran Khush, William Fearon, Yasuhiro Honda
Journal: Journal of the American College of Cardiology (2015)
Placebo-Controlled Fracture Trials in Osteoporosis — Comment on the Article by Rosen and Khosla
Authors: C. Michael Stein, Wayne A. Ray
Journal: New England Journal of Medicine (2010)

Rosen and Khosla review the arguments that are often advanced to provide support for placebo-controlled fracture trials in osteoporosis, which we discuss in our article. The undeniable crux of these arguments is that such trials are the most direct and cost-effective way to obtain high-quality scientific evidence of the efficacy and safety of new therapies. Nevertheless, because patients are involved, it is unethical to withhold a treatment that has been proved to prevent major harm such as fractures. Rosen and Khosla acknowledge this fact, noting that “trial design and implementation should not supersede patient welfare.” Thus, ethical considerations must be . . .
Le protoxyde d'azote améliore la tolérance des endoscopies digestives hautes: résultats d'une étude prospective randomisée en double aveugle
Authors: F Fumex, K Delaunay-Tardy, C Barthélémy, J Bourgis, C Chapelle, O Dumas, V Lepilliez, E Grève, M Cambou, JC Audigier
Journal: Endoscopy (2011)

Introduction: Malgré le développement des endoscopes de petit diamètre, le recours à la sédation pour la réalisation des endoscopies digestives reste courant du fait de la mauvaise tolérance de certains patients. Nous rapportons les résultats d'une étude prospective randomisée en double aveugle évaluant la faisabilité et la tolérance du protoxyde d'azote pour la réalisation des endoscopies digestives hautes.
NOCTURNAL HYPERTENSION IS ASSOCIATED WITH IMPAIRED CENTRAL HEMODYNAMICS IN HYPERTENSIVE PATIENTS WITH MORNING BLOOD PRESSURE SURGE
Authors: Won-Kyung Lee, Jaewon Oh, Chan Joo Lee, Sungha Park, Sang-Hak Lee, Seok-Min Kang, Donghoon Choi
Journal: Journal of the American College of Cardiology (2016)
Abstract 1979: Algebraic factorization of gene expression profiles reveals subtype-specific drug sensitivities among 54 breast cancer cell lines
Authors: William J. Gibb, Eric Collisson, James Korkola, Laura Heiser, Anguraj Sadanandam, Wen-Lin Kuo, Zhi Hu, Jian-Hua Mao, Nicholas Wang, Nora Bayani, Jessica Billig, Safiyyah Ziyad, Sophi Lewis, Heidi Feiler, Lakshmi Jakkula, Denise Wolf, Marc Lenburg, Paul Spellman, Joe Gray
Journal: Cancer Research (2010)

Abstract Breast cancer is a heterogeneous disease, with reproducible and prognostically important subclasses. Breast cancer cell lines are widely used to study preclinical investigational agents, but the relationships, if any, between breast cancer subclass and drug response are not well understood. To help bridge this gap, we have profiled drug responses across a large panel of well-annotated breast cancer cell lines. In order to translate in vitro drug responses into clinically useful predictions, it is important that the cell line panel be organized into subtypes representative of the cancer subtype diversity found in the clinic. Recent studies have demonstrated that an algebraic clustering method known as “non-negative matrix factorization” (NMF) can be applied to gene expression profiles to resolve clinically meaningful cancer subtypes in greater detail than achievable using other clustering methods. To test whether NMF improves our ability to resolve drug sensitivities in breast cancer cell lines, we clustered pretreatment gene expression profiles of 54 breast cancer cell lines using two different methods: (1) NMF-based consensus clustering and (2) hierarchical consensus clustering. Using NMF-based consensus, we identified five robust subtypes (two Basal-A, one Basal-B and two Luminal classes). In contrast, using hierarchical consensus clustering, we could identify only three robust subtypes (one Basal-A, one Basal-B and one Luminal class). The drug response profiles were then segregated by subtype to determine whether either of the two clustering methods improves our ability to resolve drug sensitivities. Of the 67 drug compounds included in our study, the 5-subtype NMF-based classification scheme revealed three compounds (AG1024, CPT-11 and topotecan) exhibiting subtype-specific drug effects (p&amp;lt;0.1) that are undetectable using the 3-subtype hierarchical clustering. The statistical significance of drug sensitivity was gauged using the Kruskal-Wallis rank sum test, adjusted for false discovery rate Q=0.05. In conclusion, NMF consensus clustering can be used to detect drug response patterns that would otherwise go undetected. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1979.
99mTc DMSA Scan Predicts Dilating Vesicoureteral Reflux in Young Children With a First Febrile Urinary Tract Infection a Population-Based Cohort Study
Authors: Dom-Gene Tu, Chien-Kuo Tai
Journal: Clinical Nuclear Medicine (2014)

Department of Life Science and Institutes of Molecular Biology and Biomedical Science, National Chung Cheng University, Chia-Yi; and Center of General Education, Chia Nan University of Pharmacy & Science, Tainan; and Department of Nuclear Medicine, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chia-Yi, Taiwan Department of Life Science and Institutes of Molecular Biology and Biomedical Science, National Chung Cheng University, Chia-Yi, Taiwan, [email protected]
A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort
Authors: Kathryn L. Terry, Helena Schock, Renée T. Fortner, Anika Hüsing, Raina N. Fichorova, Hidemi S. Yamamoto, Allison F. Vitonis, Theron Johnson, Kim Overvad, Anne Tjønneland, Marie-Christine Boutron-Ruault, Sylvie Mesrine, Gianluca Severi, Laure Dossus, Sabina Rinaldi, Heiner Boeing, Vassiliki Benetou, Pagona Lagiou, Antonia Trichopoulou, Vittorio Krogh, Elisabetta Kuhn, Salvatore Panico, H. Bas Bueno-de-Mesquita, N. Charlotte Onland-Moret, Petra H. Peeters, Inger Torhild Gram, Elisabete Weiderpass, Eric J. Duell, Maria-Jose Sanchez, Eva Ardanaz, Nerea Etxezarreta, Carmen Navarro, Annika Idahl, Eva Lundin, Karin Jirström, Jonas Manjer, Nicholas J. Wareham, Kay-Tee Khaw, Karl Smith Byrne, Ruth C. Travis, Marc J. Gunter, Melissa A. Merritt, Elio Riboli, Daniel W. Cramer, Rudolf Kaaks
Journal: Clinical Cancer Research (2016)

Abstract Purpose: About 60% of ovarian cancers are diagnosed at late stage, when 5-year survival is less than 30% in contrast to 90% for local disease. This has prompted search for early detection biomarkers. For initial testing, specimens taken months or years before ovarian cancer diagnosis are the best source of information to evaluate early detection biomarkers. Here we evaluate the most promising ovarian cancer screening biomarkers in prospectively collected samples from the European Prospective Investigation into Cancer and Nutrition study. Experimental Design: We measured CA125, HE4, CA72.4, and CA15.3 in 810 invasive epithelial ovarian cancer cases and 1,939 controls. We calculated the sensitivity at 95% and 98% specificity as well as area under the receiver operator curve (C-statistic) for each marker individually and in combination. In addition, we evaluated marker performance by stage at diagnosis and time between blood draw and diagnosis. Results: We observed the best discrimination between cases and controls within 6 months of diagnosis for CA125 (C-statistic = 0.92), then HE4 (0.84), CA72.4 (0.77), and CA15.3 (0.73). Marker performance declined with longer time between blood draw and diagnosis and for earlier staged disease. However, assessment of discriminatory ability at early stage was limited by small numbers. Combinations of markers performed modestly, but significantly better than any single marker. Conclusions: CA125 remains the single best marker for the early detection of invasive epithelial ovarian cancer, but can be slightly improved by combining with other markers. Identifying novel markers for ovarian cancer will require studies including larger numbers of early-stage cases. Clin Cancer Res; 22(18); 4664–75. ©2016 AACR. See related commentary by Skates, p. 4542
TCT-295 Temporal Evolution Of Coronary Vasomotor Function In Infarcted And Remote Myocardium Following Percutaneous Coronary Intervention For Acute Myocardial Infarction – A H 2 15 O PET Study
Authors: Paul F. Teunissen, Stefan A. Timmer, Ibrahim Danad, Lourens F. Robbers, Hendrik J. Harms, Pieter G. Raijmakers, Adriaan A. Lammertsma, Albert C. van Rossum, Niels van Royen, Paul Knaapen
Journal: Journal of the American College of Cardiology (2014)
P310 ANABOLIC ANDROGENIC STEROIDS (AAS) ILLICIT USE IS A RAPIDLY GROWING CAUSE OF DRUG-INDUCED LIVER INJURY (DILI): A PROSPECTIVE SERIES FROM THE SPANISH–LATIN-AMERICAN DILI REGISTRY
Authors: I. Medina-Cáliz, A. González-Jiménez, M. Robles-Díaz, C. Stephens, M. Cabello, B. García-Muñoz, M. García-Cortés, R. Alcántara, R. González-Grande, M. Jiménez, P. Rendón, J.M. Navarro, I.M. Méndez, F. Bessone, P. Ginés, I. Alfaro, J.R. Brahm, R. Paraná, M.I. Schinoni, M. Prieto, M. García-Eliz, M. Romero-Gómez, R. Calle-Sanz, A.F. González-Ramirez, A. Crespillo, M.I. Lucena, R.J. Andrade
Journal: Journal of Hepatology (2014)
Opsoclonus Due to Diphenhydramine Poisoning
Authors: Shaun D Carstairs, Aaron B Schneir
Journal: New England Journal of Medicine (2010)

A 20-year-old woman was evaluated at the hospital 2 hours after ingesting 5 g of diphenhydramine in a suicide attempt. She had a generalized seizure en route to the hospital and several more in the emergency department. Electrocardiography revealed sinus tachycardia (172 beats per minute) with a QRS duration of 172 msec. Physical examination was remarkable for rapid horizontal, vertical, and rotatory conjugate movements of the eyes, diagnosed as opsoclonus (see video at NEJM.org). Opsoclonus consists of involuntary, irregular, back-to-back, multivectorial, saccadic eye movements while the gaze is fixed. Seen primarily in association with autoimmune processes after viral infection and . . .
Abstract 5121: Acquired inactivating ARID2 mutations in lung non small cell carcinoma
Authors: Audrey Didelot, Eric Letouzé, Gilles Manceau, Karine pallier, Cecile Guichard, Aurélie Cazes, Elizabeth Fabre, Jessica Zucman-rossi, Pierre Laurent-Puig, Helene F. blons
Journal: Cancer Research (2012)

Abstract The genetic alterations involved in the development lung adenocarcinoma (ADC) have been widely characterized allowing the identification of the most frequent oncogenes or tumor suppressor genes linked to this malignancy. Most studies have focus on proliferation pathway, anti-apoptotic factors or cell cycle alterations. Here we show that alterations in chromatin remodeling complexes are frequent in lung ADC. Chromatin structure plays a key role in the regulation of tissue-specific gene expression during development and differentiation therefore it is not surprising that proteins implicated in remodeling complexes play a role in cancer development. For example, mutations have been found in genes belonging to the SWI/SNF complex in different tumors. In lung cancer BRG1 knockout was shown to potentiate tumor development and mutations were recently identified in tumors by the use of a very sensitive method: massive parallel DNA pyrosequencing that suggests the presence of the alteration in cell subclones. In the course of identifying novel chromatin remodeling complex genes implicated in lung ADC development we analyzed a series of 82 lung adenocarcinomas by SNP array and looked for the presence of homozygous deletions on the entire genome. Three regions of homozygous deletions in known tumor suppressor genes CDKN2A, FHIT and PTEN and in JARID2, which is involved in chromatin remodeling, were found in more than 2 samples. Another ARID-domain containing gene; ARID2 was found deleted in one sample and we therefore decided to screen both ARID-domain genes for mutations by direct sequencing on cryopreserved tumor tissues. One missense somatic mutation was found in JARID2 and 6/82 tumors had ARID2 alterations predicted to inactivate the protein in at least 4 out of 6 samples. Indeed 3 mutations were frameshift or non-sense, one specimen had a homozygous deletion and 4 tumors demonstrated loss of heterozygosity associated to the mutation. Our results indicate that ARID2 inactivation is a common feature of lung cancer development and provide new insight on the impact of chromatin remodeling alteration in lung ADC. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5121. doi:1538-7445.AM2012-5121